EQS-News: NeuroOne(R) to Host Virtual Investor Webinar on Thursday, March 12, 2026 at 11:30 a.m. Eastern Time

EDEN PRAIRIE, MINN - February 26, 2026 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, announced today that it will hold a virtual investor webinar on Thursday, March 12, 2026 at 11:30 a.m. Eastern Time.

Management will host the webinar to provide a corporate update, discuss the company’s growth plans, and provide updates on its platform technologies, applications, and commercialization. A question-and-answer session will follow. To participate, please use the following information:

Virtual Investor Webinar

Date: Thursday, March 12, 2026 Time: 11:30 a.m. Eastern time U.S. Dial-In (Toll Free): 888-506-0062 International Dial-In: 973-528-0011 Participant Access Code: 358063 Webcast: NMTC Virtual Investor Webinar

Please join at least five minutes before the start of the call to ensure timely participation.

A playback of the call will be available through Thursday, March 26, 2026. To listen to the replay, please call 877-481-4010 within the United States or 919-882-2331 when calling internationally, using replay passcode 53635. A webcast replay will also be available using the webcast link above through Thursday, March 26, 2026.

About NeuroOne

NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering combination diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery and spinal cord stimulation programs. For more information, visit nmtc1.com.

IR Contact MZ Group – MZ North America NMTC@mzgroup.us

View the original release on www.newmediawire.com